Asia Pacific Sepsis Diagnostics Market

The Asia Pacific sepsis diagnostics market is expected to grow from US$ 131.79 million in 2021 to US$ 249.70 million by 2028. It is estimated to record a CAGR of 9.6% from 2021 to 2028.

Increase in Funding and Support for Sepsis Diagnostics Research to Bolster Asia Pacific Sepsis Diagnostics Market Growth During Forecast Period

The rising need for rapid diagnostics for sepsis fueled the research activities by key players in recent years. Existing players and start-ups in sepsis diagnostics are well supported financially by government and research organizations. In April 2020, Cytovale Inc. announced its partnership with the Biomedical Advanced Research and Development Authority (BARDA) for sepsis diagnosis in patients suffering from infectious respiratory diseases, including COVID-19. The research was estimated to stand at US$ 5.9 million, with a contribution of ~ US$ 3.83 million by BARDA.

Additionally, the National Institute of General Medical Sciences (NIGMS) intends to use the NIH SBIR/STTR program to support preclinical and clinical sepsis studies to develop improved diagnostic tools and therapies. Diagnostics companies are continuously securing funding to establish rapid sepsis diagnostic tests. For instance, in June 2021, HelixBind secured a US$ 3 million grant from the National Institutes of Health (NIH) to support the testing of its rapid diagnostic platform for invasive infections associated with sepsis. The financial support aided the research and led to the evolution of novel biomarkers for sepsis diagnosis. Biomarkers offer a tool for facilitating early diagnosis, identifying patient populations at high risk of complications, and monitoring the disease's progression, which are critical assessments for appropriate therapy and improvement in patient outcomes. Also, the launch of effective treatments and ongoing clinical trials will provide beneficial opportunities for the Asia Pacific sepsis diagnostics market during the forecast period.

Asia Pacific Sepsis Diagnostics Market Overview

The Asia Pacific sepsis diagnostics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. The market growth in Asia Pacific countries is attributed to rising healthcare expenditure, rapid economic development in countries such as India and China, increasing prevalence of sepsis, and rising utilization of novel techniques. However, inadequate reimbursements and rising healthcare costs reduce the use of novel diagnostic techniques, which restrains the market growth.

Asia Pacific Sepsis Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Sepsis Diagnostics Strategic Insights

Strategic insights for the Asia Pacific Sepsis Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Sepsis Diagnostics Report Scope

Asia Pacific Sepsis Diagnostics Regional Insights

The geographic scope of the Asia Pacific Sepsis Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Asia Pacific Sepsis Diagnostics Market Segmentation

The Asia Pacific sepsis diagnostics market is segmented on the basis of product, technology, method, test type, pathogen, end user, and country.

Based on product, the Asia Pacific sepsis diagnostics market is segmented into instruments, reagents and assays, blood culture media, and software. The blood culture media segment held the largest market share in 2021.

Based on technology, the Asia Pacific sepsis diagnostics market is segmented into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology. The microbiology segment held the largest market share in 2021. The market for the molecular diagnostics segment is sub segmented into polymerase chain reaction, peptide nucleic acid-fluorescent in situ hybridization, syndromic panel-based testing, and microarrays.

Based on method, the Asia Pacific sepsis diagnostics market is bifurcated into automated diagnostics and conventional diagnostics. The conventional diagnostics segment held a larger market share in 2021.

Based on test type, the Asia Pacific sepsis diagnostics market is bifurcated into point-of-care tests and laboratory tests. The laboratory tests segment held a larger market share in 2021.

Based on pathogen, the Asia Pacific sepsis diagnostics market is segmented into bacterial sepsis, fungal sepsis, and others. The bacterial sepsis segment held the largest market share in 2021.

Based on end user, the Asia Pacific sepsis diagnostics market is segmented into hospitals, pathology and reference laboratories, and others. The hospitals segment held the largest market share in 2021.

Based on country, the Asia Pacific sepsis diagnostics market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China dominated the market share in 2021.

Abbott; BD; bioMerieux SA; Danaher (Beckman Coulter); F. HOFFMANN-LA ROCHE LTD.; Immunexpress Inc.; Luminex Corporation; T2 Biosystems, Inc.; and THERMO FISHER SCIENTIFIC INC. are among the leading companies operating in the Asia Pacific sepsis diagnostics market.